2021
DOI: 10.1016/j.blre.2020.100757
|View full text |Cite
|
Sign up to set email alerts
|

Second primary malignancies in multiple myeloma: A review

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

4
37
1
1

Year Published

2021
2021
2024
2024

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 40 publications
(43 citation statements)
references
References 70 publications
4
37
1
1
Order By: Relevance
“…With the increasingly longer survival of MM, second primary malignancies gained more significance 38 . In a population-based study of Sweden, the incidence of second primary malignancy was 5.5% after a median follow-up of 2.5 years 39 .…”
Section: Discussionmentioning
confidence: 99%
“…With the increasingly longer survival of MM, second primary malignancies gained more significance 38 . In a population-based study of Sweden, the incidence of second primary malignancy was 5.5% after a median follow-up of 2.5 years 39 .…”
Section: Discussionmentioning
confidence: 99%
“…It is possible that the change from the main clone to subclones during MM treatment causes a change in the clinical and hematological phenotype of MM and, thus, explains the inefficiency of the previously conducted therapy. Noteworthy, patients with MM or its precursors have an increased risk of developing secondary primary malignancies (SPMs), such as myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), and others [ 64 , 65 , 66 , 67 ]. The origin of these tumors is likely related to the genotoxic action of some therapeutic agents [ 65 , 68 , 69 , 70 , 71 , 72 , 73 , 74 ], although an excess risk for hematopoietic neoplasms other than MM in MGUS patients supports an idea that endogenous factors play an essential role in SPMs’ development [ 9 , 75 , 76 , 77 ].…”
Section: Clinical Manifestation Of Multiple Myeloma and Recent Research Approachesmentioning
confidence: 99%
“…Notably, a significant increase in mutation burden and specific mutational signature have been reported in MM patients exposed to high-dose melphalan [ 54 , 59 , 63 , 145 , 146 ]. Melphalan (and to a lesser extent cyclophosphamide) is also associated with an increased risk of SPMs in MM patients [ 64 , 68 , 69 , 71 , 72 , 147 , 148 , 149 , 150 ]. The line of chemotherapeutic drugs has been consistently elaborated upon with novel therapeutic agents in recent years.…”
Section: Clinical Manifestation Of Multiple Myeloma and Recent Research Approachesmentioning
confidence: 99%
“…Multiple myeloma (MM) is a hematological cancer which arises from abnormal antibody producing white blood plasma cells (1). MM affects approximately 500,000 people and results iñ 100,000 deaths annually (2,3) being currently considered treatable but rarely curable (4,5). There are several MM chemotherapy treatment regimens currently in use, among which eleven include bortezomib (6) (Table 1).…”
Section: Introductionmentioning
confidence: 99%